4th Quarter - Report

COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC) for COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC)

Firm
Client
Income
—
Expenses
$90,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

S. 289 - The American Cures Act, provisions related to investment in research and development H.R. 1537, S. 1878 - The Advancing Hope Act, provisions related to FDA product review. H.R. 6 - The 21st Century Cure Act, Provision related to investment in research and development, provision related to FDA product review. Draft bill - The Senate Innovating for Healthier Americans Act, Provisions related to investment in research and development; provisions related to the FDA product review. Discussions related to Marathon's Sale of Legacy Products,Precision Medicine and Education about Marathon's Initiatives and the role of Marathon Pharmaceuticals, LLC as a rare disease company

LobbyistCovered position, as disclosed
GREGORY ARONIN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1537 (114th), S. 1878 (114th), S. 289 (114th), H.R. 6 (114th)

Budget/Appropriations BUD

HR 2029 - Consolidated Appropriations Act of 2016; provisions related to FDA product review.

LobbyistCovered position, as disclosed
GREGORY ARONIN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2029 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.